Steinar Aamdal

• Aamdal, Elin; Skovlund, Eva; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian & Herlofsen, Oluf [Show all 17 contributors for this article] (2022). Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment. ESMO Open. ISSN 2059-7029. 7(5), p. 1–10. doi: 10.1016/j.esmoop.2022.100588. Full text in Research Archive Show summary

  Background: We have previously reported that the safety and efficacy of ipilimumab in real-world patients with metastatic melanoma were comparable to clinical trials. Few studies have explored health-related quality of life (HRQL) in real-world populations receiving checkpoint inhibitors. This study reports HRQL in real-world patients receiving ipilimumab and assesses the prognostic value of patient-reported outcome measures. Patients and methods: Ipi4 (NCT02068196) was a prospective, multicentre, interventional phase IV trial. Real-world patients (N = 151) with metastatic melanoma were treated with ipilimumab 3 mg/kg intravenously as labelled. HRQL was assessed by the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire at baseline and after 10-12 weeks. Results: The European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire was completed by 93% (141/151 patients) at baseline, and by 82% at 10-12 weeks. Poor performance status and elevated C-reactive protein (CRP) were associated with worse baseline HRQL. Clinically relevant and statistically significant deteriorations in HRQL from baseline to weeks 10-12 were reported (P <0.05). Baseline physical functioning [hazard ratio (HR) 1.96, P = 0.016], role functioning (HR 2.15, P <0.001), fatigue (HR 1.60, P = 0.030), and appetite loss (HR 1.76, P = 0.012) were associated with poorer overall survival independent of performance status, lactate dehydrogenase (LDH), and CRP. We further developed a prognostic model, combining HRQL outcomes with performance status, LDH, and CRP. This model identified three groups with large and statistically significant differences in survival. Conclusions: Systemic inflammation is associated with impaired HRQL. During treatment with ipilimumab, HRQL deteriorated significantly. Combining HRQL outcomes with objective risk factors provided additional prognostic information that may aid clinical decision making.

• Lee, Che-Jui; Modave, Elodie; Boeckx, Bram; Kasper, Bernd; Aamdal, Steinar & Leahy, Michael G. [Show all 13 contributors for this article] (2022). Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial. International Journal of Molecular Sciences. ISSN 1661-6596. 23(10). doi: 10.3390/ijms23105689.
• Ellingsen, Espen Basmo; Aamdal, Elin; Guren, Tormod Kyrre; Lilleby, Wolfgang; Brunsvig, Paal Fr. & Mangsbo, Sara M [Show all 11 contributors for this article] (2022). Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: Long-Term follow-up of three phase i clinical trials. Journal for ImmunoTherapy of Cancer (JITC). 10(5), p. 1–13. doi: 10.1136/jitc-2021-004345. Full text in Research Archive Show summary

  Background Therapeutic cancer vaccines represent a promising approach to improve clinical outcomes with immune checkpoint inhibition. UV1 is a second generation telomerase-targeting therapeutic cancer vaccine being investigated across multiple indications. Although telomerase is a near-universal tumor target, different treatment combinations applied across indications may affect the induced immune response. Three phase I/IIa clinical trials covering malignant melanoma, non-small cell lung cancer, and prostate cancer have been completed, with patients in follow-up for up to 8 years. Methods 52 patients were enrolled across the three trials. UV1 was given as monotherapy in the lung cancer trial and concurrent with combined androgen blockade in the prostate cancer trial. In the melanoma study, patients initiated ipilimumab treatment 1 week after the first vaccine dose. Patients were followed for UV1-specific immune responses at frequent intervals during vaccination, and every 6 months for up to 8 years in a follow-up period. Phenotypic and functional characterizations were performed on patient-derived vaccine-specific T cell responses. Results In total, 78.4% of treated patients mounted a measurable vaccine-induced T cell response in blood. The immune responses in the malignant melanoma trial, where UV1 was combined with ipilimumab, occurred more rapidly and frequently than in the lung and prostate cancer trials. In several patients, immune responses peaked years after their last vaccination. An in-depth characterization of the immune responses revealed polyfunctional CD4+ T cells producing interferon-γ and tumor necrosis factor-α on interaction with their antigen. Conclusion Long-term immunomonitoring of patients showed highly dynamic and persistent telomerase peptide-specific immune responses lasting up to 7.5 years after the initial vaccination, suggesting a plausible functional role of these T cells in long-term survivors. The superior immune response kinetics observed in the melanoma study substantiate the rationale for future combinatorial treatment strategies with UV1 vaccination and checkpoint inhibition for rapid and frequent induction of anti-telomerase immune responses in patients with cancer.

• Aamdal, Elin; Jacobsen, Kari Dolven; Straume, Oddbjørn; Kersten, Christian; Herlofsen, Oluf & Karlsen, Jarle [Show all 19 contributors for this article] (2021). Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up. International Journal of Cancer. ISSN 0020-7136. 150(1), p. 100–111. doi: 10.1002/ijc.33768. Full text in Research Archive Show summary

  Ipilimumab was the first treatment that improved survival in advanced melanoma. Efficacy and toxicity in a real-world setting may differ from clinical trials, due to more liberal eligibility criteria and less intensive monitoring. Moreover, high costs and lack of biomarkers have raised cost-benefit concerns about ipilimumab in national healthcare systems and limited its use. Here, we report the prospective, interventional study, Ipi4 (NCT02068196), which aimed to investigate the toxicity and efficacy of ipilimumab in a real-world population with advanced melanoma. This national, multicentre, phase IV trial included 151 patients. Patients received ipilimumab 3 mg/kg intravenously and were followed for at least 5 years or until death. Treatment interruption or cessation occurred in 38%, most frequently due to disease progression (19%). Treatment-associated grade 3 to 4 toxicity was observed in 28% of patients, and immune-related toxicity in 56%. The overall response rate was 9%. Median overall survival was 12.1 months (95% CI: 8.3-15.9); and progression-free survival 2.7 months (95% CI: 2.6-2.8). After 5 years, 20% of patients were alive. In a landmark analysis from 6 months, improved survival was associated with objective response (HR 0.16, P = .001) and stable disease (HR 0.49, P = .005) compared to progressive disease. Poor performance status, elevated lactate dehydrogenase and C-reactive protein were identified as biomarkers. This prospective trial represents the longest reported follow-up of a real-world melanoma population treated with ipilimumab. Results indicate safety and efficacy comparable to phase III

• Tryggestad, Anne Merete Aaland; Axcrona, Karol; Axcrona, Ulrika; Bigalke, Iris; Brennhovd, Bjørn & Inderberg, Else Marit [Show all 19 contributors for this article] (2021). Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy. The Prostate. ISSN 0270-4137. 82(2), p. 245–253. doi: 10.1002/pros.24267. Show summary

  Background: Patients with high‐risk prostate cancer (PC) can experience biochemical relapse (BCR), despite surgery, and develop noncurative disease. The present study aimed to reduce the risk of BCR with a personalized dendritic cell (DC) vaccine, given as adjuvant therapy, after robot‐assisted laparoscopic prostatectomy (RALP). Methods: Twelve weeks after RALP, 20 patients with high‐risk PC and undetectable PSA received DC vaccinations for 3 years or until BCR. The primary endpoint was the time to BCR. The immune response was assessed 7 weeks after surgery (baseline) and at one‐time point during the vaccination period. Results: Among 20 patients, 11 were BCR‐free over a median of 96 months (range: 84–99). The median time from the end of vaccinations to the last follow‐up was 57 months (range: 45–60). Nine patients developed BCR, either during (n = 4) or after (n = 5) the vaccination period. Among five patients diagnosed with intraductal carcinoma, three experienced early BCR during the vaccination period. All patients that developed BCR remained in stable disease within a median of 99 months (range: 74–99). The baseline immune response was significantly associated with the immune response during the vaccination period (p = 0.015). For patients diagnosed with extraprostatic extension (EPE), time to BCR was longer in vaccine responders than in nonresponders (p = 0.09). Among 12 patients with the International Society of Urological Pathology (ISUP) grade 5 PC, five achieved remission after 84 months, and all mounted immune responses. Conclusion: Patients diagnosed with EPE and ISUP grade 5 PC were at particularly high risk of developing postsurgical BCR. In this subgroup, the vaccine response was related to a reduced BCR incidence. The vaccine was safe, without side effects. This adjuvant first‐in‐man Phase I/II DC vaccine study showed promising results. DC vaccines after curative surgery should be investigated further in a larger cohort of patients with high‐risk PC.

• Aamdal, Elin; Inderberg, Else Marit ; Ellingsen, Espen Basmo; Rasch, Wenche; Brunsvig, Paal Fr. & Aamdal, Steinar [Show all 13 contributors for this article] (2021). Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma - Five-year follow up of a phase I/IIa trial. Frontiers in Immunology. ISSN 1664-3224. 12, p. 1–10. doi: 10.3389/fimmu.2021.663865. Full text in Research Archive
• Brunsvig, Paal Fr.; Guren, Tormod Kyrre; Nyakas, Marta Sølvi; Reisse, Claudius; Rasch, Wenche & Kyte, Jon A [Show all 10 contributors for this article] (2020). Long-term outcomes of a phase I study with UV1, a second generation telomerase based vaccine, in patients with advanced non-small cell lung cancer. Frontiers in Immunology. ISSN 1664-3224. 11:572172, p. 1–12. doi: 10.3389/fimmu.2020.572172.
• Nyakas, Marta Sølvi; Aamdal, Elin; Jacobsen, Kari Dolven; Guren, Tormod Kyrre; Aamdal, Steinar & Hagene, Kirsten Thorin [Show all 13 contributors for this article] (2019). Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clinical and Experimental Immunology. ISSN 0009-9104. 197(1), p. 74–82. doi: 10.1111/cei.13283. Full text in Research Archive
• Schöffski, Patrick; Wozniak, Agnieszka; Kasper, Bernd; Aamdal, Steinar; Leahy, Michael G. & Rutkowski, Piotr [Show all 26 contributors for this article] (2018). Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Annals of Oncology. ISSN 0923-7534. 29(3), p. 758–765. doi: 10.1093/annonc/mdx774.
• Schöffski, Patrick; Wozniak, Agnieszka; Leahy, Michael G.; Aamdal, Steinar; Rutkowski, Piotr & Bauer, Sebastian [Show all 15 contributors for this article] (2018). The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 `CREATE? European Journal of Cancer. ISSN 0959-8049. 94, p. 156–167. doi: 10.1016/j.ejca.2018.02.011.
• Sioud, Mouldy; Nyakas, Marta Sølvi; Sæbøe-Larssen, Stein; Mobergslien, Anne; Aamdal, Steinar & Kvalheim, Gunnar (2016). Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine. Case Reports in Medicine. ISSN 1687-9627. 2016. doi: 10.1155/2016/9639585.
• Kyte, Jon A; Gaudernack, Gustav; Fåne, Anne; Lislerud, Kari; Inderberg, Else Marit & Brunsvig, Paal Fr. [Show all 10 contributors for this article] (2016). T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. Oncoimmunology. ISSN 2162-4011. 5:e1249090(12). doi: 10.1080/2162402X.2016.1249090.
• Kyte, Jon A; Aamdal, Steinar; Dueland, Svein; Sæbøe-Larssen, Stein; Inderberg, Else Marit & Madsbu, Ulf Erik [Show all 9 contributors for this article] (2016). Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. ISSN 2162-4011. 5(11). doi: 10.1080/2162402X.2016.1232237.
• Andersson, Yvonne; Engebråten, Olav; Juell, Siri; Aamdal, Steinar; Brunsvig, Paal Fr. & Fodstad, Øystein [Show all 7 contributors for this article] (2015). Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin. British Journal of Cancer. ISSN 0007-0920. 113(11), p. 1548–1555. doi: 10.1038/bjc.2015.380.
• Venugopal, Balaji; Awada, Ahmad; Evans, T.R. Jeffrey; Dueland, Svein; Hendlisz, Alain & Rasch, Wenche [Show all 9 contributors for this article] (2015). A first-in-human phase i and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. ISSN 0344-5704. 76(4), p. 785–792. doi: 10.1007/s00280-015-2846-0.
• Prasmickaite, Lina; Berge, Gisle; Bettum, Ingrid Johanne; Aamdal, Steinar; Hansson, Johan & Bastholt, Lars [Show all 9 contributors for this article] (2015). Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 64(6), p. 769–776. doi: 10.1007/s00262-015-1686-4.
• Maio, Michele; Grob, Jean-Jacques; Aamdal, Steinar; Bondarenko, Igor; Robert, Caroline & Thomas, Luc [Show all 12 contributors for this article] (2015). Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. Journal of Clinical Oncology. ISSN 0732-183X. 33(10), p. 1191–1196. doi: 10.1200/JCO.2014.56.6018.
• Vihinen, Pia; Tervahartiala, Taina; Sorsa, Timo; Hansson, Johan; Bastholt, Lars & Aamdal, Steinar [Show all 11 contributors for this article] (2014). Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 64(2), p. 173–180. doi: 10.1007/s00262-014-1620-1.
• del Campo, Ana B.; Kyte, Jon A; Carretero, Javier; Zinchencko, Svitlana; Méndez, Rosa & González-Aseguinolaza, Gloria [Show all 11 contributors for this article] (2014). Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. International Journal of Cancer. ISSN 0020-7136. 134(1), p. 102–113. doi: 10.1002/ijc.28338.
• Geisler, Jürgen; Bachmann, Ingeborg M.; Nyakas, Marta Sølvi; Helsing, Per; Fjøsne, Hans E. & Mæhle, Lovise Olaug [Show all 13 contributors for this article] (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 133(20), p. 2154–2159. doi: 10.4045/tidsskr.12.1416.
• Vik-Mo, Einar O.; Nyakas, Marta Sølvi; Mikkelsen, Birthe Viftrup; Moe, Morten Carsten; Due-Tønnessen, Paulina & Suso, Else Marit Inderberg [Show all 16 contributors for this article] (2013). Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 62(9), p. 1499–1509. doi: 10.1007/s00262-013-1453-3.
• Brandberg, Yvonne; Johansson, Hemming; Aamdal, Steinar; Bastholt, Lars; Hernberg, Michaela & Stierner, Ulrika [Show all 8 contributors for this article] (2013). Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. Acta Oncologica. ISSN 0284-186X. 52(6), p. 1086–1093. doi: 10.3109/0284186X.2013.789140.
• Cohen, Roger B.; Aamdal, Steinar; Nyakas, Marta Sølvi; Cavallin, Maria; Green, Darron & Learoyd, Maria [Show all 8 contributors for this article] (2013). A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. European Journal of Cancer. ISSN 0959-8049. 49(7), p. 1521–1529. doi: 10.1016/j.ejca.2013.01.013.
• Brandberg, Y.; Aamdal, Steinar; Bastholt, L.; Hernberg, M; Stierner, U. & von der Maase, H [Show all 7 contributors for this article] (2012). Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. European Journal of Cancer. ISSN 0959-8049. 48(13), p. 2012–2019. doi: 10.1016/j.ejca.2011.11.019.
• Kaye, S.; Aamdal, Steinar; Jones, R; Freyer, G; Pujade-Lauraine, Eric & de Vries, EGE [Show all 20 contributors for this article] (2012). Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. British Journal of Cancer. ISSN 0007-0920. 106(11), p. 1728–1734. doi: 10.1038/bjc.2012.158.
• Aamdal, Steinar (2011). Current approaches to adjuvant therapy of melanoma. European Journal of Cancer. ISSN 0959-8049. 47, p. S336–S337. doi: 10.1016/S0959-8049(11)70193-9.
• Hamid, Omid; schmidt, henrik; Nissan, Aviram; Ridolfi, Laura; Aamdal, Steinar & Hansson, Johan [Show all 12 contributors for this article] (2011). A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine. ISSN 1479-5876. 9(24). doi: 10.1186/1479-5876-9-204.
• Brunsvig, Paal Fr.; Kyte, Jon A; Kersten, Christian; Sundstrøm, Stein Harald; Møller, Mona & Nyakas, Marta Sølvi [Show all 9 contributors for this article] (2011). Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial. Clinical Cancer Research. ISSN 1078-0432. 17(21), p. 6847–6857. doi: 10.1158/1078-0432.CCR-11-1385.
• Zwierzina, Heinz; Bergmann, Lothar; Fiebig, Heiner; Aamdal, Steinar; Schöffski, Patrick & Witthohn, Klaus [Show all 7 contributors for this article] (2011). The preclinical and clinical activity of aviscumine: A potential anticancer drug. European Journal of Cancer. ISSN 0959-8049. 47(10), p. 1450–1457. doi: 10.1016/j.ejca.2011.02.022.
• Hansson, Johan; Aamdal, Steinar; Bastholt, Lars; Brandberg, Yvonne; Hernberg, Micaela & Nilsson, Bo [Show all 8 contributors for this article] (2011). Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. The Lancet Oncology. ISSN 1470-2045. 12(2), p. 144–152. doi: 10.1016/S1470-2045(10)70288-6.
• Kyte, Jon A; Gaudernack, Gustav; Dueland, Svein; Trachsel, Sissel; Julsrud, Lars & Aamdal, Steinar (2011). Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients. Clinical Cancer Research. ISSN 1078-0432. 17(13), p. 4568–4580. doi: 10.1158/1078-0432.CCR-11-0184.
• Suso, Else Marit Inderberg; Dueland, Svein; Rasmussen, Anne Marie; Vetrhus, Turid; Aamdal, Steinar & Kvalheim, Gunnar [Show all 7 contributors for this article] (2011). hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 60(6), p. 809–818. doi: 10.1007/s00262-011-0991-9.
• Fox, Benard A.; Schendel, DJ; Butterfield, LH; Aamdal, Steinar; Allison, JP & Ascierto, PA [Show all 20 contributors for this article] (2011). Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine. ISSN 1479-5876. 9. doi: 10.1186/1479-5876-9-214.
• Edvardsen, Hege; Brunsvig, Paal Fr.; Solvang, Hiroko Kato; Tsalenko, A; Andersen, A & Syvanen, Ann-Christine [Show all 11 contributors for this article] (2010). SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. The Pharmacogenomics Journal. ISSN 1470-269X. 10(6), p. 513–523. doi: 10.1038/tpj.2010.6.
• Dueland, Svein; Aamdal, Steinar; Lind, Mikael; Thomas, H; Sandvold, M. Liland & Gaullier, Jean-Michel [Show all 7 contributors for this article] (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica. ISSN 0284-186X. 48(1), p. 137–145. doi: 10.1080/02841860802183620.
• Bouwhuis, Marna G.; Suciu, Stefan; Collette, Sandra; Aamdal, Steinar; Kruit, Wim H. & Bastholt, Lars [Show all 15 contributors for this article] (2009). Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon. Journal of the National Cancer Institute. ISSN 0027-8874. 101(12), p. 869–877. doi: 10.1093/jnci/djp132.
• Gunnes, Nina; Seierstad, Taral Guldahl; Aamdal, Steinar; Brunsvig, Paal Fr.; Jacobsen, Anne-Birgitte & Sundstrøm, Stein [Show all 7 contributors for this article] (2009). Assessing quality of life in a randomized clinical trial: Correcting for missing data. BMC Medical Research Methodology. ISSN 1471-2288. 9(28). doi: 10.1186/1471-2288-9-28.
• Brunsvig, Paal Fredrik; Flatmark, Kjersti; Aamdal, Steinar; Høifødt, Hanne Kleppe; Le, H & Jakobsen, E [Show all 8 contributors for this article] (2008). Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer. ISSN 0169-5002. 61(2), p. 170–176. doi: 10.1016/j.lungcan.2007.12.018.
• Faye, Ragnar Solberg; Paus, E; Maelandsmo, GM; Berner, A; Hoifodt, HK & Fodstad, O [Show all 7 contributors for this article] (2008). S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients. Melanoma research. ISSN 0960-8931. 18(2), p. 134–140.
• Kyte, Jon A; Kvalheim, Gunnar; Smebye, Kari Lislerud; Straten, PT; Dueland, S & Aamdal, Steinar [Show all 7 contributors for this article] (2007). T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 56. doi: 10.1007/s00262-006-0222-y.
• Brunsvig, Paal Fr.; Andersen, Anders; Aamdal, Steinar; Kristensen, Vessela N. & Olsen, Harald (2007). Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC Cancer. ISSN 1471-2407. 7. doi: 10.1186/1471-2407-7-197.
• Hernberg, M; Mattila, PS; Rissanen, M; Hansson, J; Aamdal, Steinar & Bastholt, L [Show all 10 contributors for this article] (2007). The prognostic role of blood lymphocyte subset distribution in patients with resected high-risk primary or regionally metastatic melanoma. Journal of immunotherapy. ISSN 1524-9557. 30.
• Brunsvig, Paal Fr.; Aamdal, Steinar; Gjertsen, Marianne Klemp; Kvalheim, Gunnar; Markowski-Grimsrud, CJ & Sve, I [Show all 11 contributors for this article] (2006). Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunology and Immunotherapy. ISSN 0340-7004. 55, p. 1553–1564.
• Jacobsen, Kari Dolven ; Fosså, Sophie Dorothea & Aamdal, Steinar (2006). Malignt melanom - diagonstikk og behandling. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 126(23), p. 3094–3097.
• Smyth, J.F; Aamdal, Steinar; Awada, A; Dittrich, C; Caponigro, F & Schöffski, P [Show all 13 contributors for this article] (2005). Phase II study of E7070 in patients with metastatic melanoma. Annals of Oncology. ISSN 0923-7534. 16, p. 158–161. doi: 10.1093/annonc/mdi016.
• Kyte, Jon A; Kvalheim, Gunnar; Aamdal, Steinar; Sæbøe-Larssen, Stein & Gaudernack, Gustav (2005). Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Therapy. ISSN 0929-1903. 12.
• Mu, L J; Kyte, Jon A; Kvalheim, Gunnar; Aamdal, Steinar; Dueland, Svein & Hauser, Markus [Show all 10 contributors for this article] (2005). Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. British Journal of Cancer. ISSN 0007-0920. 93(7), p. 749–756.
• Faye, Ragnar Solberg; Aamdal, Steinar; Høifødt, Hanne Kleppe; Jacobsen, E; Holstad, L & Skovlund, Eva [Show all 7 contributors for this article] (2004). Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clinical Cancer Research. ISSN 1078-0432. 10, p. 4134–4139.
• Bremnes, Roy Martin; Sundstrøm, Stein; Kaasa, Stein; Aasebø, Ulf & Aamdal, Steinar (2003). The value of prognostic factors in small cell lung cancer: results from a randomised multi-center study with minimum 5 year follow up. Lung Cancer. ISSN 0169-5002. 39, p. 303–313.
• Marchand, Marianne H.; Punt, C.J.A.; Aamdal, Steinar; Escudier, B.; Kruit, W.H.J. & Keilholz, U. [Show all 18 contributors for this article] (2003). Immunization of metastatic cancer patients with MAG-3 protein combined with adjuvant SBAS-2:clinical report. European Journal of Cancer. ISSN 0959-8049. 39, p. 70–77.
• Sundstrøm, Stein; Bremnes, Roy Martin; Kaasa, Stein & Aamdal, Steinar (2003). Increased survival with cisplatin and etoposide chemotherapy (EP regimen)in small cell lung cancer when compared to cyclophosphamide, epirubicin, and vincristine (CEV regimen). American Journal of Oncology Review. ISSN 1542-9520. p. 1–7.
• Faye, Ragnar Solberg; Overgaard, R.; Jebsen, P; Qvale, Geir Aksel; Høifødt, H. K. & Kvalheim, Gunnar [Show all 8 contributors for this article] (2002). Melanoma Antibody in Micrometastases in Malignant Uveal Melanoma and a Comparison of the Test Results in the Eye Tumour, the Bone Marrow and Peripheral Blood, Oral.
• Sundstrøm, Stein; Bremnes, Roy Martin; Kaasa, Stein; Aasebø, Ulf; Hatlevoll, Reidulv & Dahle, R. [Show all 13 contributors for this article] (2002). Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years¿ follow-up. Journal of Clinical Oncology. ISSN 0732-183X. 20, p. 4665–4672.
• Fodstad, Øystein; Faye, Ragnar Solberg; Høifødt, H. K.; Skovlund, Eva & Aamdal, Steinar (2001). Immunobead-based detection and characterization of circulating tumor cells in melanoma patients. Recent Results in Cancer Research. ISSN 0080-0015. 158, p. 40–50.
• Sudbø, Jon; Warloe, Trond; Aamdal, Steinar; Reith, Albrecht & Bryne, Magne (2001). Diagnosis and treatment of oral precancerous lesions. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 120(26), p. 3066–3071. Show summary

  BACKGROUND: Risk factors for oral carcinomas have been identified, but there are no reliable markers for assessing the clinical outcome in individual patients with oral precancerous lesions. DNA aneuploidy is now recognized as an early and significant event in carcinogenesis. METHODS: We identified 242 patients with oral red or white patches histologically verified as epithelial dysplasias and measured the nuclear DNA content (DNA ploidy) of the lesions to determine whether DNA ploidy could be used to predict the clinical outcome. Disease-free survival was assessed in relation to DNA ploidy and histological grade. The mean duration of follow-up was approximately eight years. RESULTS: Among 242 patients with verified epithelial dysplasia, a carcinoma developed in 48 (20%). 167 (69%) had diploid lesions, 20 (8%) had tetraploid lesions and 55 (23%) had aneuploid lesions. Of the 167 with diploid lesions, only four (1%) later developed an oral carcinoma. By contrast, 48 of 55 patients with aneuploid lesions (87%) later developed a carcinoma. INTERPRETATION: The DNA content (DNA ploidy) can be used to predict the risk for oral cancer in a wide range of oral precancerous lesions. By contrast, histological grading of the same lesions does not give any prognostic information. The clinical value of an early identification of oral lesions with malignant cell clones is substantiated by the fact that there are methods for early intervention.

• Hovig, Eivind; Myklebost, Ola; Aamdal, Steinar & Smeland, Erlend B (2001). Genterapi ved kreft. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 121(4), p. 482–488.
• Smeland, Erlend B; Prydz, Hans Peter B; Ørstavik, Karen Helene; Frøland, Stig Sophus; Aamdal, Steinar & Myklebost, Ola [Show all 15 contributors for this article] (2000). Genterapi. Status og fremtidige muligheter innen klinisk medisin, Tidlig identifikasjon og vurdering av nye metoder. Senter for medisinsk metodevurdering.
• Jungnelius, U.; Ringborg, U.; Aamdal, Steinar; Mattson, J.; Stierner, U & Ingvar, C. [Show all 13 contributors for this article] (1998). Dacarbazine-Vinddesine versus Dacarbazine-Vindesine-Cisplatin in disseminated malignanat melanoma. A randomised phase III trial. European Journal of Cancer. ISSN 0959-8049. 34(9), p. 1368–1374.
• Semb, KA; Aamdal, Steinar; Mette, E.; Ingvar, C.; Gullaksen, N. & Osmundsen, K. (1998). Zilascorb(H), a low toxicity protein synthesis inhibitor that exhibits signs of anticancer activity in malignant melanoma. Anti-Cancer Drugs. ISSN 0959-4973. 9, p. 797–802.
• Semb, KA; Aamdal, Steinar & Øian, P (1998). A capillary leak syndrom seems to explain fluid retention in cancer patients receiving docetaxel treatment. Journal of Clinical Oncology. ISSN 0732-183X. 16, p. 3426–3232.
• Semb, KA; Aamdal, Steinar; Bomann, T.; Lucas, C. & Gerard, B. (1998). Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma. Melanoma research. ISSN 0960-8931. 8, p. 565–572.
• Jungnelius, U.; Ringborg, U.; Aamdal, Steinar; Mattson, J.; Stierner, U & Ingvar, C. [Show all 12 contributors for this article] (1998). Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. European Journal of Cancer. ISSN 0959-8049. 9, p. 1368–11374.
• Semb, KA; Fodstad, Øystein; Klem, B.; Bibow, K; Osmundsen, K. & Aamdal, Steinar (1997). Zilascorb (2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anti-Cancer Drugs. ISSN 0959-4973. 3, p. 296–303.
• Semb, KA; Aamdal, Steinar; Fosså, Sophie Dorothea & Øian, P (1996). Transcapilllary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome? Journal of experimental therapeutics and oncology. ISSN 1359-4117. 1, p. 155–161.
• Semb, KA; Aamdal, Steinar; Fosså, Sophie Dorothea & Øian, P (1996). Transcapillary forces of the subcutaneous tissue in patients treated with interleukin-2 and alpha-interferon: no capillary protein leak syndrome? Journal of experimental therapeutics and oncology. ISSN 1359-4117. 1, p. 155–161.
• Flørenes, Vivi Ann; Aamdal, Steinar; Myklebost, Ola; Mælandsmo, Gunhild Mari; Bruland, Øyvind & Fodstad, Øystein (1992). Levels of mm23 mRNA in metastatic malignant melanomas. Inverse correlation to disease progression. Cancer Research. ISSN 0008-5472. 52, p. 6088–6091.

View all works in Cristin

• Straume, Oddbjørn; Geisler, Jürgen; Gullestad, Hans Petter; Nyakas, Marta Sølvi; Jacobsen, Kari Dolven & Aamdal, Steinar (2016). MEDIKAMENTELL KREFTBEHANDLING - Cytostatikaboken 8. utgave, Kapittel 34 - Malignt melanom. Universitetet i Oslo. ISBN 978-82-992331-4-9. 661 p.
• Sudbø, Jon; Reith, Albrecht; Sudbø, Asle & Aamdal, Steinar (2004). Chemoprevention of oral cancer - risk assessment, plausible intervention and monitoring. Humana Press. 15 p.
• Thoresen, G. Hege; Aamdal, Steinar & Småland, R (1999). Cytostatika Medikamentell kreftbehandling kap. 17 Andre cytostatika. Institutt for farmakoterapi og Den Norske Kreftforening. 6. 430 p.

View all works in Cristin

• Dueland, Svein; Guren, Tormod Kyrre; Boberg, Kirsten Muri; Reims, Henrik Mikael; Grzyb, Krzysztof & Aamdal, Steinar [Show all 8 contributors for this article] (2017). Acute liver graft rejection after ipilimumab therapy. Annals of Oncology. ISSN 0923-7534. 28(10), p. 2619–2620. doi: 10.1093/annonc/mdx281.
• Aamdal, Steinar; Bentzen, Heidi Beate; Borge, Ole Johan; Erikstein, Bjørn K; Grimsgaard, Sameline & Hovig, Johannes Eivind [Show all 8 contributors for this article] (2017). Åpne Nordens grenser for forskning og behandling. Aftenposten (morgenutg. : trykt utg.). ISSN 0804-3116.
• Vik-Mo, Einar O.; Nyakas, Marta Sølvi; Lote, K.; Aamdal, Steinar; Gaudernack, Gustav & Langmoen, Iver Arne [Show all 7 contributors for this article] (2013). CLINICAL EXPERIENCES WITH THERAPEUTIC DC VACCINES TARGETING AUTOLOGOUS CANCER STEM CELLS IN GLIOBLASTOMA. Cytotherapy. ISSN 1465-3249. 15(4), p. S14–S14.
• Aamdal, Steinar (2012). The importance of patient selection in treatment efficacy. Annals of Oncology. ISSN 0923-7534. 23(supp. 9), p. 32–32.
• Prasmickaite, Lina; Skrbo, Nirma; Høifødt, Hanne Kleppe; Suo, Zhenhe; Engebråten, Olav & Gullestad, Hans petter [Show all 9 contributors for this article] (2010). Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell & Melanoma Research. ISSN 1755-1471. 23(3), p. 449–451. doi: 10.1111/j.1755-148X.2010.00690.x.
• Han, L.; Aamdal, Steinar; Boven, Epie; Freyer, Gilles; Kristensen, Gunnar S Balle & Jones, R. [Show all 10 contributors for this article] (2010). Treatment profile of saracatinib (AZD0530) in combination with chemotherapy in patients with advanced ovarian carcinoma. Gynecologic Oncology. ISSN 0090-8258. 116(3), p. S60–S60.
• Aamdal, Steinar; Boven, Epie; de Vries, Elisabeth G. E.; Pujade-Lauraine, Eric; Freyer, Gilles & Jones, R. [Show all 9 contributors for this article] (2010). PHASE I STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SARACATINIB (AZD0530) PLUS CARBOPLATIN (C) AND/OR PACLITAXEL (P) IN PATIENTS WITH SOLID TUMOURS. Annals of Oncology. ISSN 0923-7534. 21, p. 171–172.
• Aamdal, Steinar; Wolchok, Jedd D.; Weber, Jeffrey S.; Hamid, Omid; O'Day, Steven J. & Schmidt, Henrik [Show all 8 contributors for this article] (2009). Changes in peripheral blood absolute lymphocyte count (ALC) may guide patient selection for continued treatment with ipilimumab. European Journal of Cancer. ISSN 0959-8049. 7(2), p. 579–579.
• Dueland, Svein; Mu, LJ; Kvalheim, Gunnar; Hauser, Markus; Waehre, Haakon & Aamdal, Steinar [Show all 7 contributors for this article] (2005). Dendritic cells transfected with allo-tumor mRNA as cancer vaccine in treatment of hormone resistant prostate cancer patients. Journal of Clinical Oncology. ISSN 0732-183X. 23, p. 176S–176S.
• Aamdal, Steinar; Kyte, Jon Amund; Dueland, Svein; Mu, LJ; Gullestad, HP & Ryder, Truls [Show all 10 contributors for this article] (2005). Phase VII trial of vaccine therapy with tumor-RNA transfected dendritic cells in patients with advanced malignant melanoma. Journal of Clinical Oncology. ISSN 0732-183X. 23, p. 175S–175S.
• Brunsvig, P.; Gjertsen, Marianne Klemp; Kvalheim, Gunnar; Aamdal, Steinar; Markowski-Grimsrud, CJ & Sve, I [Show all 11 contributors for this article] (2005). A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer. Journal of Clinical Oncology. ISSN 0732-183X. 23.
• Eide, Nils; Øvergaard, Ralf Gunnar; Jebsen, Peter; Qvale, Geir A; Faye, Ragnar Solberg & Høifødt, Hanne Kleppe [Show all 9 contributors for this article] (2004). Evalution of 9.2.27 melanoma antibody in micro metastases in malignant uveal melanoma and a comparision of the test results in the eye tumour, the bone marrow and peripheral blood.
• Gaudernack, Gustav; Kvalheim, Gunnar; Mu, L; Kyte, JA; Hauser, M. & Sæbøe-Larssen, S. [Show all 9 contributors for this article] (2003). Clinical trials of immuno-gene therapy using tumor mRNA transfected dendritic cells.
• Kyte, JA; Mu, L; Aamdal, Steinar; Hauser, M.; Lislerud, K. & Sæbøe-Larssen, S. [Show all 9 contributors for this article] (2003). Phase I/II trial of vaccine therapy with mRNA-transfected dendritic cells in patients with advanced malignant melanoma.
• Kyte, JA; Mu, L; Aamdal, Steinar; Hauser, M.; Kvalheim, Gunnar & Gaudernack, Gustav (2003). Phase I/II trial of vaccine therapy with mRNA-transfected dendritic cells in patients with advanced malignant melanoma.
• Gaudernack, Gustav; Buanes, Trond; Meo, Axel Marco; Aamdal, Steinar; Brunsvig, P. & Braathen, L.R. [Show all 10 contributors for this article] (2003). Clinical trials of a peptide based vaccine targeting telomerase.
• Sudbø, Jon; Aamdal, Steinar; Sudbø, Asle & Reith, Albrecht (2002). Chemoprevention of oral cancer - risk assessment, strategies for intervention and monitoring. In Kelloff, Gary; Hawke, Ernest & Sigman, Carole (Ed.), Cancer Chemoprevention, Vol 2; Strategies for cancer chemoprevention. Humana Press, USA.
• Eide, Nils; Øvergaard, Ralf; Jebsen, Peter W.; Qvale, Geir Aksel; Faye, Ragnar Solberg & Høifødt, H. K. [Show all 9 contributors for this article] (2002). Evaluation of 9.2.27 melanoma antibody in micrometastases in malignant uveal melanoma and a comparison of the test results in eye tumor, the bone marrow and peripheral blood.
• Eide, Nils; Faye, Ragnar Solberg; Øvergaard, Ralf; Hovland, B.; Andersen, Marie & Høifødt, H. K. [Show all 9 contributors for this article] (1999). Micrometastasis in malignt uveal melanomas.
• Eide, Nils; Øvergaard, Ralf; Kvalheim, Gunnar; Aamdal, Steinar; Faye, Ragnar Solberg & Fodstad, Øystein (1998). Mikrometastaser ved malignt uvealt melanom.
• Brunsvig, Paal Fredrik & Aamdal, Steinar (2008). New diagnostic and therapeutic approaches in non-small cell lung cancer. Unipub forlag. ISSN 978-82-8072-475-5.

View all works in Cristin